AbCellera Biologics Inc. (ABCL) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-24

Business type: Asset play

How it makes money

It earns through research fees, milestones, and royalties from partners using its antibody discovery platform, though currently reliant on occasional large licensing events.

The company provides a discovery engine that helps partners identify potential drug candidates. It generates revenue by charging upfront research fees and collecting downstream payments if those programs reach specific development milestones or achieve commercial sales.

Because the internal pipeline is early-stage, the majority of recent revenue gains were driven by licensing and royalty activity, which can be highly irregular and dependent on partners successfully advancing the molecules discovered by the company's platform.

What protects it: the moat

It attempts to protect its business through specialized proprietary platform capabilities and a new internal manufacturing facility, though competitive success remains unproven.

The company relies on its ability to target complex proteins—such as GPCRs and ion channels—that are historically difficult for traditional antibody discovery methods to address. It also asserts that its recently completed 130,000-square-foot clinical manufacturing facility provides a competitive advantage by allowing it to control supply chains and internal intellectual property.

Management claims these integrated capabilities differentiate it from peers, but the long-term effectiveness of these protections is subject to the inherent risks of drug development and market competition.

What growth costs

It must sustain heavy, ongoing spending on research and development and operating costs to advance its internal pipeline and maintain its manufacturing facility.

Growth depends on the successful advancement of its own internal drug assets, which requires significant and continuous investment in clinical trials and personnel. The company also faces ongoing fixed costs to operate its new clinical manufacturing facility.

Because these clinical assets are in early-stage development, the company continues to report operating losses and expects significant future expenditures to fund its discovery and development operations.

What could damage it

Earnings would be permanently impaired if it fails to successfully develop its own drugs or secure new partnerships, as its current revenue remains sporadic.

The company's long-term viability depends on either generating successful drug candidates in-house or maintaining the partnership model that produces milestone and royalty revenue. If it cannot advance its clinical candidates—such as ABCL635 or ABCL575—through regulatory approval, it will lose its primary mechanism for future value creation.

Similarly, because it cannot control the pace of its partners' programs, a decline in partner interest or success would eliminate the recurring revenue that currently funds its operational platform.

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Other companies in Biotechnology